Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study BioSpacePemvidutide showed a "highly statistically significant" treatment effect in patients with alcohol use disorder.Metabolic & GLP-1Read full story pharminent July 28, 2026 (Last updated: July 30, 2026) BioSpace Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Metabolic & GLP-1 Read full story Post navigation Previous: GSK to quit Stevenage for new R&D site in CambridgeNext: GSK Unveils Three-Year Restructuring to Fund Late-Stage R&D Ahead of Patent Cliff Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026